Numis Securities Ltd restated their buy rating on shares of BTG plc (LON:BTG) in a research note published on Thursday morning. They currently have a GBX 900 ($11.94) price target on the stock.

Several other equities research analysts also recently weighed in on BTG. Deutsche Bank AG reissued a buy rating and set a GBX 775 ($10.28) price objective on shares of BTG plc in a report on Thursday, September 21st. Peel Hunt reissued a hold rating and set a GBX 680 ($9.02) price objective on shares of BTG plc in a report on Wednesday, September 20th. Stifel Nicolaus reissued a buy rating and set a GBX 800 ($10.61) price objective on shares of BTG plc in a report on Wednesday, August 30th. J P Morgan Chase & Co reissued a neutral rating on shares of BTG plc in a report on Monday, September 18th. Finally, Shore Capital reissued a not rated rating on shares of BTG plc in a report on Thursday, July 13th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of GBX 780.33 ($10.35).

BTG plc (LON BTG) traded down 0.14% during midday trading on Thursday, hitting GBX 713.00. The stock had a trading volume of 378,478 shares. BTG plc has a 52 week low of GBX 528.36 and a 52 week high of GBX 738.50. The company’s market capitalization is GBX 2.75 billion. The company’s 50-day moving average price is GBX 682.42 and its 200 day moving average price is GBX 662.79.

TRADEMARK VIOLATION NOTICE: “BTG plc’s (BTG) Buy Rating Reaffirmed at Numis Securities Ltd” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/btg-plcs-btg-buy-rating-reaffirmed-at-numis-securities-ltd/1613719.html.

BTG plc Company Profile

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Analyst Recommendations for BTG plc (LON:BTG)

Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with Analyst Ratings Network's FREE daily email newsletter.